Recent 8-K filings for DRMA
Highest-materiality recent filing
Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance
- STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).
- Inflammatory lesion count reduced by 16.8 vs 13.1 (p<0.001); non-inflammatory by 17.3 vs 12.4 (p<0.001).
-
Dermata shareholders approve 2021 equity plan increase to 402,214 shares
Elected David Hale, Steven Mento Ph.D., and Brittany Bradrick as Class II directors.
-
Cash and cash equivalents $6.9M as of Mar 31, 2026, down from $7.5M at Dec 31, 2025; net ATM proceeds of $2.0M.
-
Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M
Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.
-
Director Mary Fisher resigns from Dermata board, effective March 31, 2026
Resignation due to her employer being acquired; no longer permitted to serve on board.
-
Dermata Therapeutics dismisses Baker Tilly, appoints CBIZ CPAs as new auditor
Baker Tilly dismissed as independent auditor effective January 31, 2026.
-
Dermata increases ATM offering capacity by $705K; previously sold $3.45M under same program
Filed prospectus supplement to increase maximum aggregate offering under ATM by $705,000.
-
Dermata raises $4.1M (up to $12.4M) in private placement at $2.04/share for OTC acne kit launch
Gross proceeds of ~$4.1M upfront; potential additional ~$8.3M from full warrant exercise for total up to $12.4M.
-
Dermata terminates Villani license, pivots to OTC skin care
Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.
-
Dermata Therapeutics pivots to OTC; plans acne kit launch mid-2026, reports Q3 cash $4.7M
Cash and cash equivalents of $4.7M as of Sep 30, 2025; expected to fund operations into Q2 2026.
-
Dermata Therapeutics ups ATM stock offering by $1.79M after prior $1.66M sales
Filed prospectus supplement to increase aggregate ATM offering by $1,792,315 in common stock.
-
Dermata reports statistically significant Phase 3 XYNGARI acne data vs placebo at EADV 2025
IGA 2-point reduction + clear/almost clear at Week 12: 29.4% XYNGARI vs 15.2% placebo (p<0.001).
-
Dermata pivots to OTC dermatology, withdraws XYNGARI IND, plans acne kit launch mid-2026
Strategic shift to prioritize OTC dermatology products sold directly to consumers.
-
Dermata Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq non-compliance notice on May 14, 2025 due to bid price below $1.00.
-
Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M
XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.
-
Dermata Therapeutics to effect 1-for-10 reverse stock split effective August 1, 2025
Reverse stock split at 1:10 ratio effective 12:01 a.m. ET on August 1, 2025.
-
Dermata Therapeutics stockholders approve reverse stock split and director elections at 2025 meeting
Stockholders elected Mary Fisher and Andrew Sandler as Class I directors for three-year terms.
-
Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule
Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.
-
Dermata Therapeutics changes auditor to Baker Tilly after Moss Adams merger
Moss Adams merged into Baker Tilly US, LLP effective June 3, 2025; audit committee approved Baker Tilly as successor.
-
Dermata initiates XYNGARI drug product manufacturing; Phase 3 STAR-2 trial expected Q4 2025
Manufacturing for XYNGARI drug product initiated for Phase 3 STAR-2 trial; trial start expected Q4 2025.
-
Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing
Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.
-
Dermata: XYNGARI Phase 3 STAR-1 acne trial meets co-primary endpoints; cash $9.7M
XYNGARI Phase 3 STAR-1 achieved statistically significant results on all co-primary endpoints at all time points vs placebo.
-
Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne
IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.
-
Dermata raises ~$6.2M via warrant exercise at reduced price; issues new warrants
4,834,470 existing warrants exercised at reduced price of $1.284/share, yielding $6.2M gross proceeds.
-
Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance
STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).
-
Dermata Therapeutics receives Nasdaq delisting notice for failing minimum stockholders' equity
Nasdaq notified Dermata on March 25, 2025, of non-compliance with $2.5M minimum stockholders' equity rule.
-
Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025
Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.
-
Dermata raises $2.55M private placement at $1.27/unit with insider participation
Gross proceeds $2.55M; net ~$2.4M from 2,007,880 shares (or pre-funded warrants) and same number of warrants.
-
Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis
Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.
-
Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M
Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.
-
Dermata raises $3.5M gross in private placement; expects cash runway into Q2 2025
Gross proceeds $3.5M from 1,912,569 shares/pre-funded warrants + Series A & B warrants at $1.83/unit.
-
Dermata Therapeutics reports Q2 2024 results; DMT310 Phase 3 trial enrollment over 50%
Net cash $4.9M at June 30, 2024, down from $7.4M at Dec 31, 2023; expects to fund ops into Q4 2024.
-
Dermata Therapeutics ups ATM offering by $505K to $1.66M total
Increased maximum aggregate offering price under ATM agreement with H.C. Wainwright by $505,000 to $1,662,761.
-
Dermata Therapeutics enters ATM equity facility for up to ~$1.16M
ATM Agreement with H.C. Wainwright for at-the-market issuance of common stock up to $1,157,761 aggregate market value.
-
Dermata regains Nasdaq minimum bid price compliance; delisting risk resolved
Received Nasdaq notice on June 4, 2024 that company is in compliance with $1.00 minimum bid price requirement.
-
Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule
Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.
-
Dermata raises $2.66M via immediate exercise of warrants at reduced price; issues new warrants
Exercise of 516,336 warrants at reduced exercise price of $5.16 per share for cash gross proceeds of ~$2.66M.
-
Dermata gets 180-day Nasdaq extension; files 1:15 reverse stock split to regain compliance
Received Nasdaq extension until November 11, 2024 to meet $1.00 minimum bid price.
-
Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024
Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.
-
Dermata Therapeutics to effect 1:15 reverse stock split on May 16, 2024
Shareholders authorized reverse split ratio between 1:5 and 1:30; Board selected 1:15 on May 8.
-
Dermata shareholders approve reverse stock split (1:5-1:30) and equity plan expansion
Stockholders approved reverse stock split at ratio from 1:5 to 1:30, exact ratio to be set by Board.
-
Dermata Therapeutics reports FY 2023 net loss; cash runway into Q3 2024; Phase 3 acne trial underway
Cash and equivalents $7.4M as of Dec 31, 2023 vs $6.2M in 2022; expects to fund ops into Q3 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material